Allos Initiates Confirmatory Phase III Study of Folotyn
By Marie Powers
Thursday, August 18, 2011
While its planned merger with AMAG Pharmaceuticals Inc. and a rival offer for AMAG from hedge fund MSMB Capital Management swirled in the background, Allos Therapeutics Inc. enrolled the first patient in its Phase III randomized trial (PDX-017) evaluating Folotyn (pralatrexate injection) in patients with previously undiagnosed peripheral T-cell lymphoma (PTCL). The post-approval study is open to newly diagnosed patients with PTCL who have achieved an objective response following initial treatment with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) or a CHOP-like regimen.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.